There is no registration fee for this event. For the in-person symposium in Atlanta, GA preregistration is required as seating is limited.  

This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Lilly, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and TG Therapeutics Inc.

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of chronic lymphocytic leukemia.

Learning Objectives
Upon completion of this activity, participants should be able to

• Individualize the selection of systemic therapy for patients with newly diagnosed chronic lymphocytic leukemia (CLL), considering clinical presentation, biomarker profile, coexisting medical conditions and patient preferences.
• Discuss available Phase III data demonstrating the superior efficacy and safety of Bruton’s tyrosine kinase (BTK) inhibition compared to standard chemoimmunotherapy as first-line therapy for patients with CLL, and use this information to evaluate and select available front-line options.
• Appraise the Phase III data supporting the FDA approval of acalabrutinib for newly diagnosed or previously treated CLL, and identify patients for whom treatment with this agent may be appropriate.
• Assess the FDA approval of venetoclax in combination with obinutuzumab as front-line therapy for CLL, and appropriately integrate this regimen into current treatment decision-making.
• Analyze how age, performance status, prior therapeutic exposure and other biologic and disease-related factors affect the selection and sequencing of therapy for patients with relapsed/refractory (R/R) CLL.
• Implement a plan of care to recognize and manage side effects and toxicities associated with recently approved and emerging systemic therapies employed in the management of CLL.
• Develop an understanding of the biologic rationale for and appreciate available efficacy and safety data with the use of chimeric antigen receptor T-cell therapy for patients with R/R CLL, and consider the potential future role of this novel therapeutic approach.
• Recall available and emerging data with other novel agents, combinations and strategies currently under investigation in CLL, and, where applicable, refer eligible patients for trial participation.

CE Credit
A CME and ABIM MOC credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

FACULTY — Dr Jain and Dr Mato have no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Pagel — Consulting Agreements: AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Epizyme Inc, Gilead Sciences Inc, MorphoSys, Seagen Inc. Dr Woyach — Advisory Committee: AbbVie Inc, ArQule Inc, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company; Consulting Agreements: AbbVie Inc, ArQule Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company; Data and Safety Monitoring Board/Committee: Gilead Sciences Inc.

MODERATOR — John N Allan, MD – Advisory Committee: AbbVie Inc, ADC Therapeutics, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Epizyme Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc; Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, a member of the Roche Group, Janssen Biotech Inc, TG Therapeutics Inc; Faculty Bureau: AbbVie Inc, BeiGene Ltd, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Lilly, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and TG Therapeutics Inc.

Omni Atlanta Hotel at CNN Center
190 Marietta St NW
Atlanta, GA 30303
Hotel Phone: (404) 659-0000

Meeting Room
International Ballroom (E-F) - North Tower (M2 Floor)

Directions
The Omni Atlanta Hotel at CNN Center is conveniently located within walking distance of the Georgia World Congress Center, where the ASH Annual Meeting is taking place.